echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Using CRISPR gene editing to improve cell therapy Vertex reaches a $1.2 billion collaboration

    Using CRISPR gene editing to improve cell therapy Vertex reaches a $1.2 billion collaboration

    • Last Update: 2021-09-13
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    On August 24, Vertex Pharmaceuticals and Arbor Biotechnologies announced that the two parties will launch a new collaboration to use Arbor's proprietary CRISPR gene editing technology to enhance the development of innovative cell therapies for the treatment of serious diseases

    Arbor was co-founded by renowned scholar Dr.
    Feng Zhang with the aim of discovering new gene-editing proteins and developing "tailor-made" nuclease therapy for diseases based on these proteins
    The company has discovered more than 60 nuclease families and more than 70 CRISPR transposases (transposases), which are 6 times and 30 times the number published in the literature

    The new agreement between Arbor and Vertex builds on the partnership established between the two parties in 2018
    According to this new cooperation agreement, Vertex will obtain the right to use Arbor's technology to research and develop ex vivo engineered cell therapies to develop fully differentiated, insulin-producing low-immune islet cells for the treatment of type 1 diabetes; and research and development A new generation method for the treatment of diseases such as sickle cell disease and beta thalassemia

    Under the terms of the agreement, Arbor will receive an advance payment and is eligible for potential milestone payments of up to $1.
    2 billion
    In addition, Vertex will also pay tiered royalties for future net sales of any products that may result from this cooperation

    Reference materials:

    [1] Vertex and Arbor Biotechnologies Establish New Partnership to Develop Novel ex vivo Engineered Cell Therapies.
    Retrieved 2021-08-24, from https:// /en/Vertex-and-Arbor-Biotechnologies-Establish-New-Partnership-to-Develop-Novel-ex-vivo-Engineered-Cell-Therapies.

    (The original text has been deleted)

    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.